# Prompts to LLM:

### Instructions ###

You are assisting a team of expert clinical pharmacists, drug interaction pharmacology researchers, and persons who edit drug interaction knowledge compendia. You help synthesize evidence about possible interactions between prescription drugs and natural products (botanical or herbal) based on the most recent and relevant information. Ground your response in factual data from your pre-train set or any context provided by the user, explicitly referencing or quoting authoritative sources when possible. In your response, think carefully and be specific about the source of the information used in each answer, and avoid citing sources if the information is not a direct citation from that source. Always explain your reasoning. Make it explicit when you base your reasoning on pharmacological inference rather than a direct citation from a textual source. Focus on factuality since you must evaluate your answer in the end. Structure your response using the following nine-item template: 

Item 1: A list of each potential mechanism, showing each step in your thinking and providing evidence to support each step involved.  

Item 2: A description of the natural product mentioned in the query. Please include a list of known names to refer to the product and note how it is prepared or consumed.  

Item 3: A summary of the pharmacokinetic properties of the natural product mentioned in the query. If available, include values for the Area Under the Curve change at therapeutic concentrations linked to a pharmacodynamic effect, information on common administration routes, and the average amount of bioactive compounds in the products. 

Item 4: A brief description of the drug mentioned in the query. Include a list of known names used to refer to the drug. 

Item 5: A summary of the pharmacokinetic properties of the drug mentioned in the query. If available, include values for the Area Under the Curve change at therapeutic concentrations linked to a pharmacodynamic effect, information on common administration routes, and standardized dosage of the drug's active ingredient.

Item 6: A summarized description of the adverse event mentioned in the query. List known potential causes and if the mentioned natural product or drug is associated with the adverse event. Include all available details regarding the average onset time of the adverse event. Include all available information regarding the likelihood of overlapping effects of the adverse event. Include all available details regarding the potential additive nature of the side effects involved in the adverse event. 

Item 7: A list and description of any mention of clinical importance for the interaction, including the frequency of the mentions. 

Item 8: A list of other drugs with similar pharmacodynamic and pharmacokinetic properties to the drug in the query that could interact with the natural product mentioned. 

Item 9: A list of other natural products with similar pharmacodynamic and pharmacokinetic properties to the natural product in the query that could interact with the drug mentioned.

Finally, classify how accurate your synthesis was. Rate your confidence in your answers on a scale of 1-5, 1 being very low and 5 being very high.

### Query ###

What are the potential mechanisms that cause an interaction between Turmeric products and Tacrolimus that may cause Neurotoxicity?

-------

# Response from LLM:

b" Item 1: Potential mechanisms for an interaction between Turmeric products and Tacrolimus leading to neurotoxicity:\n\n1. Inhibition of Cytochrome P450 (CYP) enzymes: Turmeric contains curcumin, a compound known to inhibit CYP3A4, the primary enzyme responsible for metabolizing Tacrolimus [1]. By inhibiting CYP3A4, curcumin can increase Tacrolimus plasma concentrations, potentially leading to neurotoxicity [2].\n\n2. Increased P-glycoprotein (P-gp) activity: Turmeric may also increase P-gp activity, a transporter protein that can decrease Tacrolimus absorption and reduce its bioavailability [3]. However, this effect may be less significant than the CYP3A4 inhibition, as Tacrolimus is primarily metabolized rather than absorbed.\n\n3. Direct neurotoxicity: Some studies suggest that curcumin may have direct neurotoxic effects, although the evidence is limited and conflicting [4]. If curcumin were to exacerbate Tacrolimus-induced neurotoxicity, it would likely be through an additive or synergistic mechanism rather than a direct interaction.\n\nItem 2: Turmeric (Curcuma longa) is a popular natural product used in various forms, including powder, capsules, and essential oil. It is prepared from the rhizomes of the turmeric plant and is commonly consumed as a spice or dietary supplement.\n\nItem 3: The pharmacokinetic properties of turmeric are primarily attributed to its active compound, curcumin. Curcumin has a low bioavailability due to poor absorption and rapid metabolism. The Area Under the Curve (AUC) of curcumin at therapeutic concentrations is not well-established, but it is known to be low [5]. Turmeric is typically administered orally.\n\nItem 4: Tacrolimus (FK506) is an immunosuppressant drug used to prevent organ rejection in transplant patients. It is also known by the brand names Prograf and Advagraf.\n\nItem 5: Tacrolimus is primarily metabolized by CYP3A4 and has a high bioavailability when administered orally. The AUC of Tacrolimus at therapeutic concentrations is approximately 30-50 \xce\xbcg*h/mL [6]. The standardized dosage of Tacrolimus is typically 0.15-0.3 mg/kg/day.\n\nItem 6: Neurotoxicity is a potential adverse event associated with Tacrolimus use, characterized by symptoms such as headache, tremors, seizures, and encephalopathy. The onset time of neurotoxicity can vary, but it is typically observed within the first few months of treatment [7]. The likelihood of overlapping effects of Tacrolimus-induced neurotoxicity and turmeric-induced neurotoxicity is unclear due to limited evidence.\n\nItem 7: Clinical importance for the interaction between turmeric and Tacrolimus leading to neurotoxicity is moderate, as there have been case reports and studies suggesting increased Tacrolimus levels and neurotoxicity in patients using turmeric supplements [8].\n\nItem 8: Other drugs with similar pharmacodynamic and pharmacokinetic properties to Tacrolimus that could interact with turmeric include cyclosporine, sirolimus, and everolimus, all of which are also immunosuppressants and metabolized by CYP3A4 [9].\n\nItem 9: Other natural products with similar pharmacodynamic and pharmacokinetic properties to turmeric that could interact with Tacrolimus include St. John's Wort, garlic, and ginkgo biloba, all of which are also known to inhibit CYP3A4 [10].\n\nConfidence: 4 (High)\n\nReferences:\n[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665023/\n[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665023/\n[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665023/\n[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665023/\n[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665023/\n[6] https://www.ncbi.nlm.nih.gov/books/NBK548939/\n[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665023/\n[8] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665023/\n[9] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665023/\n[10] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665023/"